New FebriDx® Study | Journal of Antimicrobial Chemotherapy
16 May 2024
Antimicrobial resistance (AMR) is a growing threat to global health, driven largely by the overuse of antibiotics. In primary care, lower respiratory tract infections (LRTIs) are a common reason for antibiotic prescriptions - often unnecessarily as many LRTIs are viral, and do not benefit from antibiotics.
A new independent study by UK researchers, published in the Journal of Antimicrobial Chemotherapy, has found that using FebriDx led to a substantial reduction in antibiotic prescribing intentions for patients with LRTIs.
In the study, doctors at nine different GP practices used the FebriDx test on patients who were deemed likely to receive antibiotic prescriptions for their chest infections. After testing, clinicians were more confident that antibiotics were not required in 51% of patients, while for 31% of patients, the test strengthened their decision to prescribe antibiotics.
Overall, use of FebriDx to guide antibiotic prescribing for LRTI in primary care was associated with a substantial reduction in prescribing intentions.
This research highlights that FebriDx has the potential to be a powerful tool to help address the global challenge of AMR. By providing clinicians with rapid and accurate information about the nature of a patient's infection, FebriDx can empower them to make more informed decisions.
Click here to read the paper.
A new independent study by UK researchers, published in the Journal of Antimicrobial Chemotherapy, has found that using FebriDx led to a substantial reduction in antibiotic prescribing intentions for patients with LRTIs.
In the study, doctors at nine different GP practices used the FebriDx test on patients who were deemed likely to receive antibiotic prescriptions for their chest infections. After testing, clinicians were more confident that antibiotics were not required in 51% of patients, while for 31% of patients, the test strengthened their decision to prescribe antibiotics.
Overall, use of FebriDx to guide antibiotic prescribing for LRTI in primary care was associated with a substantial reduction in prescribing intentions.
This research highlights that FebriDx has the potential to be a powerful tool to help address the global challenge of AMR. By providing clinicians with rapid and accurate information about the nature of a patient's infection, FebriDx can empower them to make more informed decisions.
Click here to read the paper.
